CD274 and neoplasm: (54) reported promising results for the efficiency of the PD-L1-inhibitor pembrolizumab for the treatment of different solid, MSI-positive tumors, the tumor response to pembrolizumab in MSI-positive PDCAs was rather modest with 18% in the KEYNOTE-158 Study (54, 55).